On March 14, 2025, the Octoparms® II vena cava filter independently developed by Kossel Medtech (Suzhou) Co., Ltd. was approved by the National Drug Administration (NMPA). (registration number is 20253130576). In addition, the Seledora® coronary scoring balloon catheter developed by the subsidiary Mixin Medtech was also approved by the National Medical Products Administration (NMPA) today. (registration number is 20253030586).

Vena Cava Filter

Three core advantages upgraded

The stability upgraded

• Retrieval hook is smooth to reduce delivery resistance

• Raise and widen the balance arm to improve long-term stability

• New anchoring hook design, anti-displacement, anti-penetration

• Diamond-shaped filter can effectively block thrombus of 4mm and above

• 
  

The specification upgraded

The delivery system upgraded

• Releasable and interlocking arm design, to achieve controlled release in a transjugular way

• Double markers with a space of 30mm, help measure the diameter of the inferior vena cava

• The sheath is braided to enhance support and bending resistance and establish a stable path

• The sheath end is thread design, anti-shift, easy to approach

The delivery system

Octoparms® vena cava filter, clinically proven, is a domestic umbrella-shaped filter with excellent performance, it has been recognized by nearly 2,000 hospitals in China since its launch, benefiting tens of thousands of patients.

Coming out of the clinic need and serving the clinic need, Octoparms® Ⅱ, an upgrade of the Octoparms® vena cava filter, will be more widely used and accepted for the benefit of more patients